Cargando…

Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF-α antagonists

BACKGROUND: Infections which complicate rheumatic diseases such as Rheumatoid Arthritis (RA) and Spondyloarthropathy (SpA) (Psoriatic Arthritis [PA] and Ankylosing Spondylitis [AS]), may cause significant morbidity and mortality. However, among the studies on the incidence rate (IR) of infections in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Germano, Valentina, Cattaruzza, Maria Sofia, Osborn, John, Tarantino, Aurora, Di Rosa, Roberta, Salemi, Simonetta, D’Amelio, Raffaele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994399/ https://www.ncbi.nlm.nih.gov/pubmed/24655394 http://dx.doi.org/10.1186/1479-5876-12-77

Ejemplares similares

Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies
por: Bogunia-Kubik, Katarzyna, et al.
Publicado: (2021)

TCD4(pos) lymphocytosis in rheumatoid and psoriatic arthritis patients following TNFα blocking agents
por: Picchianti Diamanti, Andrea, et al.
Publicado: (2017)

The role of ultrasonography in the diagnosis of rheumatoid arthritis and peripheral spondyloarthropathies
por: Sudoł-Szopińska, Iwona, et al.
Publicado: (2014)

Analysis of Gut Microbiota in Rheumatoid Arthritis Patients: Disease-Related Dysbiosis and Modifications Induced by Etanercept
por: Picchianti-Diamanti, Andrea, et al.
Publicado: (2018)

The Changing Face of Spondyloarthropathies Under TNF α Blockade
por: Elkayam, Ori, et al.
Publicado: (2008)

Could Early Rheumatoid Arthritis Resolve After Periodontitis Treatment Only?: Case Report and Review of the Literature
por: Salemi, Simonetta, et al.
Publicado: (2014)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Frequency and Predictors of Opioid Use in Rheumatoid Arthritis and Seronegative Spondyloarthropathy Patients
por: Sahebari, Maryam, et al.
Publicado: (2022)

Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review
por: Picchianti Diamanti, Andrea, et al.
Publicado: (2016)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

Myeloid-related protein (MRP) 8 and MRP 14 in rheumatoid arthritis and spondyloarthropathy
por: De Rycke, L, et al.
Publicado: (2003)

Spondyloarthropathy and rheumatoid arthritis: two different diseases, a similar cytokine network
por: Moura, R A, et al.
Publicado: (2010)

A multilectin affinity approach for comparative glycoprotein profiling of rheumatoid arthritis and spondyloarthropathy
por: Bhattacharjee, Mitali, et al.
Publicado: (2013)

TNF-α Blockers Showed Prophylactic Effects in Preventing COVID-19 in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthropathies: A Case–Control Study
por: Salesi, Mansour, et al.
Publicado: (2021)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
por: Wei, Kai, et al.
Publicado: (2022)

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
por: Jeon, Chan Hong
Publicado: (2022)

ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial
por: Seegobin, Seth D, et al.
Publicado: (2014)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies
por: Ferrufino, Cheryl P, et al.
Publicado: (2018)

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis
por: Verstappen, M., et al.
Publicado: (2020)

Are DMARDs enough to prevent surgery in rheumatoid hands?
por: Sim, Yeap Swan
Publicado: (2015)

Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases
por: Laganà, Bruno, et al.
Publicado: (2019)

Plasma Levels of IL-37 and Correlation with TNF-α, IL-17A, and Disease Activity during DMARD Treatment of Rheumatoid Arthritis
por: Zhao, Ping-Wei, et al.
Publicado: (2014)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]
Publicado: (2019)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

Expanding the armamentarium for the spondyloarthropathies
por: Peloso, Paul M, et al.
Publicado: (2004)

The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2014)

Healthcare professionals’ perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis
por: Voshaar, M. J. H., et al.
Publicado: (2022)

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Nathalie, Luurssen-Masurel, et al.
Publicado: (2021)

Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis
por: Furuya, Hidekazu, et al.
Publicado: (2013)

Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
por: Lim, Heejin, et al.
Publicado: (2018)

Undifferentiated spondyloarthropathy in Korea: focusing on peripheral arthritis.
por: Kim, Tae Hwan, et al.
Publicado: (2002)

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2011)

Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
por: Bykerk, Vivian P, et al.
Publicado: (2012)

The Impact of DMARD and Anti-TNF Therapy on Functional Characterization of Short-Term T-Cell Activation in Patients with Rheumatoid Arthritis – A Follow-Up Study
por: Szalay, Balázs, et al.
Publicado: (2014)

Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis
por: Kruithof, Elli, et al.
Publicado: (2005)

The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
por: Jani, Meghna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_82jna4knki9f97i4lbo3a7qs98